24 GHP Q4 2025 n the ever-evolving pharmaceutical, medical device and combination product industries, regulations are always changing, with frequent updates to standards such as ISO 10993, ICH, and the EU MDR. Cormica exists to help its clients stay ahead of these changes, with its strong network of subject matter experts and technical specialists being committed to monitoring, interpreting, and implementing new regulatory requirements. “This proactive approach allows us to adapt quickly, refine our testing strategies, and provide clients with the most current, compliant solutions,” says Mark. “While keeping pace with evolving regulations presents challenges, it also strengthens our expertise and reinforces our position as a trusted partner in global product development and release.” Indeed, Cormica is proud to offer end-to-end testing and regulatory support across its clients’ product lifecycles, from early material selection and late-stage R&D to registration, product release, and post-market monitoring. Mark tells us, “By supporting every stage, from IND and CMC to NDA submission, clinical evaluation, and ongoing batch release, Cormica helps clients accelerate development timelines, meet global compliance requirements, and maintain confidence in product quality throughout its lifecycle.” At the foundation of Cormica’s offering I Established in 1962 as a small testing facility with big dreams, Cormica has grown into an industry leader in medical device and pharmaceutical testing, enabling its clients to launch and release their medical products globally in a way that is both compliant and efficient, in turn improving patients’ lives. Making it all happen is a large team of ardent scientists, technicians, and subject matter experts, who are situated across its laboratories in the US, UK, and Europe. Recognised as 2025’s Leading Pharmaceutical & Medical Device Testing Specialists, we are keen to learn more about Cormica from Chief Executive Officer, Mark Hammond. are core values of ‘We Do What Is Right’, ensuring it upholds ethical standards and delivers accurate and reliable results with integrity every time; ‘We Have Ownership’, where every team member takes pride in their work and strives to go above and beyond client expectations with commitment and accountability; ‘We Work Together’, supporting each other and celebrating collective success; ‘We Continually Improve’, with a relentless focus on achieving excellence by developing expertise and enhancing services on an ongoing basis; and ‘We Are Our Community’, which means it is dedicated to giving back by supporting initiatives that improve patients’ lives. Guided by these values daily, the Cormica team are driven to deliver fast, high-quality, compliant testing across its GMP, GLP, and ISO 17025 accredited laboratories. “We pride ourselves on consistency and reliability of our results, supported by robust quality systems and deep technical expertise,” Mark states. “Our teams work collaboratively across sites in the UK, US, and EU to provide clients with rapid, dependable data that meets global regulatory expectations, helping them bring safe, effective pharmaceutical and medical device products to market with confidence.” “We’re very pleased with the testing conducted for us. Cormica demonstrated exceptional professionalism and efficiency, and the results were delivered exactly as promised. They made the entire process seamless. We will be returning for future testing projects.” -Client review So, how will Cormica continue innovating into the future? The company remains as ambitious as ever as it looks to continue growing both organically and through acquisition, with plans to expand it’s network of laboratories across the EU and US and enhance its service offering. To aid in making this happen, it is investing heavily into its existing sites, with this including new facilities, upgraded AHU systems, and the installation of solar panels to enhance capacity, sustainability, and efficiency. A key priority for the coming year will be the integration of a unified Laboratory Information Management System (LIMS) to streamline workflows, improve data integrity, and enhance client experience across all Cormica laboratories. “By continually expanding our capabilities, harmonising processes across sites, and investing in our people and technology, we’re strengthening our mission to improve patients’ lives through reliable, high-quality testing and expert support,” says Mark. As a result of its investment, Cormica will be poised to deliver even faster, more reliable, and fully connected testing service worldwide, and we can’t wait to see it all come into fruition. Contact: Aiden Tingley Company: Cormica Website: www.cormica.com Ensuring Medical Device Quality and Compliance
RkJQdWJsaXNoZXIy MTUyMDQwMA==